[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR028996A1 - USE OF A COMBINATION OF MTP INHIBITORS AND HMG INHIBITORS - COA REDUCTASA FOR THE MANUFACTURE OF MEDICINES, MEDICINES THAT UNDERSTAND AND THE PROCEDURE FOR PREPARATION - Google Patents

USE OF A COMBINATION OF MTP INHIBITORS AND HMG INHIBITORS - COA REDUCTASA FOR THE MANUFACTURE OF MEDICINES, MEDICINES THAT UNDERSTAND AND THE PROCEDURE FOR PREPARATION

Info

Publication number
AR028996A1
AR028996A1 ARP000103129A ARP000103129A AR028996A1 AR 028996 A1 AR028996 A1 AR 028996A1 AR P000103129 A ARP000103129 A AR P000103129A AR P000103129 A ARP000103129 A AR P000103129A AR 028996 A1 AR028996 A1 AR 028996A1
Authority
AR
Argentina
Prior art keywords
medicines
inhibitors
combination
manufacture
hmg
Prior art date
Application number
ARP000103129A
Other languages
Spanish (es)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of AR028996A1 publication Critical patent/AR028996A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere al uso de una combinacion de al menos un inhibidor de MTP seleccionado (componente A), en donde R1 a R7, D, E y L (correspondiente al sustituyente A1), tienen su significado dado en la memoria descriptiva; en donde R1 a R4, A, D, E y Z (correspondiente al sustituyente A2), tienen su significado dado en la memoria descriptiva; en donde R1 a R4, D, E y L (correspondiente al sustituyente A3), tienen su significado dado en la memoria descriptiva; en donde R1, R2, A, D, E y L (correspondiente al sustituyente A4), tienen su significado dado en la memoria descriptiva y en donde R1 a R3, D, E, G, L, M (correspondiente al sustituyente A5), tienen su significado dado en la memoria descriptiva; y un inhibidor de HMg-CoA reductasa (componente B) para la fabricacion de un medicamento para la lucha contra enfermedades del sistema cardiocirculatorio, a medicamentos que contienen esta combinacion y a su procedimiento de obtencion.This refers to the use of a combination of at least one selected MTP inhibitor (component A), wherein R1 to R7, D, E and L (corresponding to substituent A1), have their meaning given in the specification; wherein R1 to R4, A, D, E and Z (corresponding to substituent A2), have their meaning given in the specification; wherein R1 to R4, D, E and L (corresponding to substituent A3), have their meaning given in the specification; wherein R1, R2, A, D, E and L (corresponding to substituent A4), have their meaning given in the specification and where R1 to R3, D, E, G, L, M (corresponding to substituent A5) , have their meaning given in the specification; and an HMg-CoA reductase inhibitor (component B) for the manufacture of a medicament for the fight against diseases of the cardiocirculatory system, to medications containing this combination and to its method of obtaining.

ARP000103129A 1999-06-25 2000-06-22 USE OF A COMBINATION OF MTP INHIBITORS AND HMG INHIBITORS - COA REDUCTASA FOR THE MANUFACTURE OF MEDICINES, MEDICINES THAT UNDERSTAND AND THE PROCEDURE FOR PREPARATION AR028996A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19929065A DE19929065A1 (en) 1999-06-25 1999-06-25 Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor

Publications (1)

Publication Number Publication Date
AR028996A1 true AR028996A1 (en) 2003-06-04

Family

ID=7912459

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103129A AR028996A1 (en) 1999-06-25 2000-06-22 USE OF A COMBINATION OF MTP INHIBITORS AND HMG INHIBITORS - COA REDUCTASA FOR THE MANUFACTURE OF MEDICINES, MEDICINES THAT UNDERSTAND AND THE PROCEDURE FOR PREPARATION

Country Status (12)

Country Link
EP (1) EP1196194A2 (en)
JP (1) JP2003503342A (en)
AR (1) AR028996A1 (en)
AU (1) AU5680900A (en)
CA (1) CA2376881A1 (en)
DE (1) DE19929065A1 (en)
DO (1) DOP2000000022A (en)
GT (1) GT200000099A (en)
PE (1) PE20010302A1 (en)
SV (1) SV2004000109A (en)
UY (1) UY26218A1 (en)
WO (1) WO2001000183A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10030375A1 (en) * 2000-06-21 2002-01-03 Bayer Ag Use of MTP inhibitors to lower ppTRL
BR0306292A (en) * 2002-02-28 2004-08-24 Japan Tobacco Inc Ester compound and medicinal use thereof
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc Ester derivative and medicinal use thereof
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
DE102011007272A1 (en) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
CN109053927A (en) * 2018-08-08 2018-12-21 中山大学 A kind of amphipathic sodium alginate derivative of the group containing vitamin B12 and its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (en) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indole and -azaindole derivatives
DE19546919A1 (en) * 1995-12-15 1997-06-19 Bayer Ag N-heterocyclically substituted phenylacetic acid derivatives
DE19546918A1 (en) * 1995-12-15 1997-06-19 Bayer Ag Bicyclic heterocycles
DE19615265A1 (en) * 1996-04-18 1997-12-04 Bayer Ag New pyridazino, pyrimido, pyrazino and triazinoindoles
IL129744A0 (en) * 1996-11-27 2000-02-29 Pfizer Apo b-secretion/mtp inhibitory amides
EP1024804A4 (en) * 1997-05-01 2001-03-21 Bristol Myers Squibb Co Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels

Also Published As

Publication number Publication date
DOP2000000022A (en) 2008-08-15
CA2376881A1 (en) 2001-01-04
UY26218A1 (en) 2001-01-31
WO2001000183A2 (en) 2001-01-04
DE19929065A1 (en) 2000-12-28
SV2004000109A (en) 2004-05-07
AU5680900A (en) 2001-01-31
PE20010302A1 (en) 2001-04-12
WO2001000183A3 (en) 2001-05-10
EP1196194A2 (en) 2002-04-17
GT200000099A (en) 2001-12-13
JP2003503342A (en) 2003-01-28

Similar Documents

Publication Publication Date Title
CY1115289T1 (en) Methods of Treatment Against Inflammation-Related Illness
BRPI0413363A (en) dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
DOP2000000022A (en) COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES.
BRPI0617165A2 (en) MEK INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE THEREOF
WO2007053641A3 (en) A-type procyanidins and inflammation
AR058433A1 (en) DERIVATIVE OF 1,1-DIOXIDE OF 1,4-BENZOTIAZEPIN, PROCEDURE FOR PREPARATION, MEDICATIONS UNDERSTANDING THIS COMPOSITE AND ITS USE
CL2007003604A1 (en) Pharmaceutical composition for oral administration comprising the amorphous 17-aminogeldanamycin compound; and its use in the treatment of cancer.
NI201000041A (en) DERIVATIVES AND COMPOSITIONS INCLUDING QUINAZOLINONE 6-, 7-, OR 8 - SUBSTITUTE AND METHODS TO USE THE SAME
BRPI0418330A (en) solid compositions of low solubility drugs and poloxamers
PA8577901A1 (en) PHARMACEUTICAL FORMULATION
BR0308613A (en) Combination of Organic Compounds
ECSP088246A (en) NEW DERIVATIVES OF BENZOTIAZOLONA
BR0315580A (en) Methylene Urea Derivatives
CL2011001131A1 (en) Use of a formulation that serves to prepare a drug for an injection, which minimizes inflammation at the site of injection of an antibody, and where the formulation comprises a 2h7 antibody and variants of the antibody and polyvinylpyrrolidone (pvp)
BRPI0507652A (en) pharmaceutical compositions comprising a benzoidiazepine derivative and an rsv fusion protein inhibitor
BRPI0620229A8 (en) formulation
BRPI0507654A (en) pharmaceutical composition comprising a benzodiazepine derivative and an rsv fusion protein inhibitor
WO2007128086A3 (en) Novel viral replication inhibitor
BRPI0415053B8 (en) p-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
BRPI0817275A2 (en) Pharmaceutical combination of aliskiren and valsartan
NO20074933L (en) Pharmaceutical composition comprising an indolylmaleimide derivative
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
ECSP055745A (en) DERIVATIVES OF 1- (4-BENCIL-PIPERAZIN-1-IL) -3-FENIL-PROPENONA
CR9391A (en) DERIVATIVES OF INDANIL-PIPERAZINAS, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
UY32299A (en) LIQUID PHARMACEUTICAL COMPOSITIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure